"Cyberchondriac" numbers stagnant: Harris Interactive

Share this article:
For the first time in 10 years, the number of people seeking healthcare information online has decreased – from 160 million in 2007, to 150 million in 2008 – according to the Harris Poll.

Online healthcare seekers, referred to by Harris as “cyberchondriacs,” represent 66% of all adults in the US, and 81% of adults online, according to a company statement. In 1998, the Harris Poll counted 54 million cyberchondriacs. That number has increased every year until 2008.

“The rapid growth in the number of cyberchondriacs seems to have plateaued, but we do not know if this pause is temporary or more permanent,” said Humphrey Taylor, chairman of the Harris Poll, in a statement.

The Harris Poll also found that 47% of cyberchondriacs have discussed the information they obtained online with their doctors, and 49% have gone online to look for information after a doctor's appointment, according to phone survey data. Eighty-six percent reported a belief that the information they found online was reliable, and 89% said they were successful in obtaining healthcare information online.

The Harris Poll surveyed 1,010 adults by telephone within the US between July 8 and 13, 2008, according to Harris Interactive. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...